Skip to Content

ABVC BioPharma Inc ABVC

Morningstar Rating
$1.21 +0.02 (1.68%)
View Full Chart
Unlock our analysis with Morningstar Investor

About Quantitative Ratings

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.

Price vs Fair Value

ABVC is trading within a range we consider fairly valued.
Price
$1.18
Fair Value
$2.30
Uncertainty
Extreme
1-Star Price
$68.88
5-Star Price
$3.95
Economic Moat
Pmw
Capital Allocation
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if ABVC is a good fit for your portfolio.

News

Trading Information

Previous Close Price
$1.19
Day Range
$1.171.27
52-Week Range
$0.679.60
Bid/Ask
$1.17 / $1.21
Market Cap
$10.35 Mil
Volume/Avg
50,107 / 2.1 Mil

Key Statistics

Price/Earnings (Normalized)
Price/Sales
5.95
Dividend Yield (Trailing)
Dividend Yield (Forward)
Total Yield

Company Profile

ABVC BioPharma Inc is a clinical-stage biopharmaceutical company with an active pipeline of six drugs and one medical device (ABV-1701/Vitargus) under development. For its drug products, it is focused on utilizing its licensed technology to conduct proof-of-concept trials through Phase II of the clinical development process. The firm is specialized in botanically based solutions that deliver high efficacy with low toxicity for improved health outcomes.
Sector
Healthcare
Industry
Biotechnology
Stock Style Box
Small Core
Total Number of Employees
30

Valuation

Metric
ABVC
Price/Earnings (Normalized)
Price/Book Value
0.67
Price/Sales
5.95
Price/Cash Flow
Price/Earnings
ABVC

Financial Strength

Metric
ABVC
Quick Ratio
0.32
Current Ratio
0.46
Interest Coverage
−6.38
Quick Ratio
ABVC

Profitability

Metric
ABVC
Return on Assets (Normalized)
−82.35%
Return on Equity (Normalized)
−241.77%
Return on Invested Capital (Normalized)
−106.12%
Return on Assets
ABVC
See how this stock stacks up to its competitors with Morningstar Investor

Biotechnology Industry Comparables

Ticker
Name
Morningstar Rating for Stocks
Economic Moat
Market Cap
NVO
Novo Nordisk A/S ADRCxdk$537.7 Bil
VRTX
Vertex Pharmaceuticals IncDqtxvj$110.2 Bil
REGN
Regeneron Pharmaceuticals IncRyxfvv$105.9 Bil
MRNA
Moderna IncCnr$37.9 Bil
ARGX
argenx SE ADRFbzlr$23.7 Bil
BNTX
BioNTech SE ADRZjh$22.2 Bil
ALNY
Alnylam Pharmaceuticals IncPnzjrwg$20.5 Bil
BMRN
Biomarin Pharmaceutical IncDrnmbqx$17.0 Bil
RPRX
Royalty Pharma PLC Class AMjwck$13.9 Bil
INCY
Incyte CorpWhytp$13.7 Bil

Sponsor Center